Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg,...

13
Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor Faculty Advisor: Prof. Mohan V. Tatikonda ([email protected] ) February 22, 2012

Transcript of Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg,...

Page 1: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Operational Analysis

National Gene Vector Biorepository

Aaron Boeke, Kevin Largent, Kyle McClurg, Sean SeacatNot present: Patrick Doumas and Peter Tichenor

Faculty Advisor: Prof. Mohan V. Tatikonda ([email protected])

February 22, 2012

Page 2: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Agenda

• Background• Investigation• Problem Definition• Project Overview • Questions

Page 3: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Background• Mission of the National Gene Vector

Biorepository (NGVB) is to provide gene therapy investigators with a variety of services that can enhance their research.o Archiving Serviceso Insertion Site Analysiso Pharmacology and Toxicology Resourceso Reagent Repository 

• Housed within the Department of Medical and Molecular Genetics in the IUSM.o Made possible by a grant from the National

Center for Research Resources (NCRR)

Page 4: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Objective

• NGVB requested assistance from a Kelley MBA team to:o (1) analyze workflow; o (2) make suggestions for improved internal

and external communications; and o (3) develop a system to manage inputs and

outputs.

Page 5: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Defining the Problem• Discussed concerns with NGVB manager

o Weekly meetings• Toured the NGVB Facilities

o Certification Labo Freezer and Deep-Freeze Storage Sites

• Met with staff to better understand gene therapy research environmento Troy Hawkins - Molecular Diagnostics

Supervisoro Lisa Duffy - Certification Lab Supervisor

Page 6: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Defining the Problem We also reviewed:

o Standard operating procedureso Initial customer informationo Product/service catalogo Stepped through the customer’s order entry

process using the NGVB websiteo Worked to understand each step an order

goes through in the process

Page 7: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Initial Findings• Current process documentation can be enhanced

o General o Customer problems

• Lack of standardizationo Labeling and storage of productso Use of electronic database across product

lines• Uncertainty regarding the quality of the

customer's experience• Uncertainty of demand across product lines

o Difficulty in determining batch sizes, stock levels, and reorder points

Page 8: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Process Analysis• Process Flow Diagrams

o Current state mapped to gain primary understanding of the NGVB processes Observe processes to understand the

physical flow of materials, people, and information

Determine constraints and sources of variation

• Increase Service Level to the Customero Decreased turn-around time

Page 9: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.
Page 10: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Customer Analysis

• Database analysiso Variety, volume, and frequency of orders

• Qualitative interviews with local customerso Analyze experiences of customers from a

variety of perspectives new vs. repeat customers local vs. international frequent vs. infrequent 

Page 11: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Intended Deliverables • Detailed process characterization and capacity

analysis o Bottleneck identificationo Flow time analysis

• Analysis of current customer set and historical order patternso Demand forecastingo Production schedulingo Improved customer order fulfillment time

• Optimization of storage capacity

Page 12: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

IU Vector Production Facility

  • Background

o Provides gene therapy production and testing services with a focus on lentiviral gene transfer

• Project- In Project Scope Phaseo Provide detailed understanding of overhead

cost in order to appropriately price serviceso Working in compliance with FDA and

NIH regulations and guidelines

Page 13: Operational Analysis National Gene Vector Biorepository Aaron Boeke, Kevin Largent, Kyle McClurg, Sean Seacat Not present: Patrick Doumas and Peter Tichenor.

Questions?

 Thank you